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In this study, a Mn(II)-based coordination polymer with the chemical composition of {[Mn(L)(TBTA)(H2O)2]ꞏH2O}n (1) 
has been prepared by reacting Mn(OAc)2ꞏ2H2O with the flexible ligand 1,4-bis(5,6-dimethylbenzimidazol-1-yl)-2-butylene 
in the aid of the carboxylic acid ligand tetrabromoterephthalic acid (H2TBTA) through the mixed-ligand method. Its 
application value on osteosarcoma has been measured, and the internal principle is discussed simultaneously. The inhibitory 
activity of the new compound on the multiplication of osteosarcoma cells is evaluated using the Cell Counting Kit-8 
detection kit. The facilitation of the LKB1-mTORC1 signalling pathway is estimated via real-time RT-PCR. 
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Osteosarcoma is a familiar tumor, and 90% of juvenile 
metastases occur in primary lung malignant bone 
tumors. Although the survival time of patients with 
osteosarcoma combined with standard chemotherapy 
and limb-saving surgery is longer than before, the 
prognosis of patients with lung metastases remains poor 
with the improvement of treatment effect1. Bone 
metastasis accounts for 15%–20% of metastatic tumors 
in the body, which is lower than the incidence rates of 
liver and lung metastases. Malignant tumors in the lung, 
prostate, and thyroid are the most familiar primary 
tumors, taking up approximately 80% of whole cases2,3. 
Thus, understanding the principle of bone metastasis is 
important to improve the prevention and cure of bone 
metastasis. 
Nowadays, metal complexes based on benzimidazole 
derivatives with diversified structure, including cyclic 
complexes, have attracted increasing attention4. 
Benzimidazole derivatives have diverse coordination 
functions that benefit this type of metal organic 
structure5-7. Metal complexes based on benzimidazole 
have also attracted wide publicity because of their 
outstanding properties and wide applications in various 
industries, such as supramolecular chemistry, catalysis, 
luminescence, and pharmacology8-11. Benzimidazole has 
a double ring structure formed by the combination of 
imidazole and benzene. It is used in the research and 
development of new drugs. Many compounds including 
this motif were clinically admitted for application as 
anti-helminth drugs (such as thiabendazole), proton 
pump inhibitors (such as lansoprazole), antiviral drugs 
(such as enviradine), and antihypertensive drugs (such as 
telmisartan)12-15. In addition to the above concerned 
medicinal functions, benzimidazole complexes also 
possess antitumor and other related bioactivities16,17. On 
the other hand, Manganese(II) ion is the required 
co-factor in many ubiquitous enzymes. Research has 
proved that Mn(II) ion is mainly uptaken and transported 
by divalent metal transporter (DMT-1) and transferrin 
receptor (TfR), which is high expressed in some tumor 
tissues18,19. Transporting mechanism of Mn(II) in vivo 
makes Mn(II)-based compounds possible to be tumor-
targeted. Biochemically active Mn(III)-salen and 
Mn(III)-salphen compounds were reported to induce 
nuclear fragmentation and apoptosis of HeLa cells20. 
Chen and co-workers reported that Mn(II) compounds 
with N-substituted di(picolyl)amine inhibits the 
proliferation of human glioma cells (U251) and HepG-2 
cells in vitro21. 
In the present study, an innovative Mn(II)-based 
coordination polymer (CP) with the technical term 
of {[Mn(L)(TBTA)(H2O)2]ꞏH2O}n (1) was prepared 
by reacting Mn(OAc)2ꞏ2H2O with the flexible ligand 
1,4-bis(5,6-dimethylbenzimidazol-1-yl)-2-butylene  
in the aid of the carboxylic acid ligand 
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tetrabromoterephthalic acid (H2TBTA) through the 
mixed-ligand method. The prepared coordination 
polymer 1 was structurally discussed with single 
crystal X-ray diffraction and was further detected by 
infrared (IR) spectroscopy, powder X-ray diffraction 
(PXRD), elemental analyses, and thermogravimetric 
analysis (TGA). Serial biological experimentations 
were performed to measure the therapeutic effect of 
the new compound against osteosarcoma. 
 
Materials and Methods 
All reagents were analytical grade and used as 
received without further purification. Carbon, hydrogen, 
and nitrogen were analyzed using the Perkin-Elmer 
model 240C analyzer. The IR spectrum on the Nicolet 
spectrometer with KBr pellets was recorded at  
400–4000 cm−1. The PXRD pattern was obtained using 
the Bruker D8 Advance X-ray diffractometer applying 
Cu-Kα radiation (0.15418 nm) at 40 kV and 30 mA. 
TGA results were implemented via the Perkin Elmer 
thermogravimetric analyzer from roomtemperature to 
700 ℃ with a heating rate of 20 K min–1 under nitrogen 
environment. 
 
Preparation and characterization for {[Mn(L) (TBTA) 
(H2O)2]ꞏH2O}n (1) 
In a 25 mL Teflon-lined high pressure vessel,  
10 mL of H2O, 53 mg of Mn(OAc)2ꞏ2H2O, and  
48.1 mg of 34.4 mg L-1 H2TBTA were mixed to obtain 
the compound. Then, it was stored at 140 ℃ for 72 h. 
After lowering to the normal environment at a speed 
of 10 ℃ꞏh-1, pink crystals were produced by filtration 
and washing. The yield was 37.2%. Anal. Calcd. (%) 
for 1(C30H30Br4MnN4O7): C, 38.61; H, 3.24; N, 6.00. 
Found (%): C, 38.53; H, 3.79; N, 5.82. IR (KBr, cm−1, 
Fig S1): 3567 m, 1577 s, 1506 s, 1407 m, 1326 s, 
1301 m, 1212w, 1081w, 960w, 872 m. 
XRD data were obtained using the Oxford Xcalibur E 
diffractometer. Statistical analysis of diverse intensity 
data was recorded via CrysAlisPro software, and the 
result was converted into HKL format. The pattern of 
SHELXS applying the direct method was used to form 
the fundamental structure, and the pattern of SHELXL-
2014 applying the least square method was modified. 
Various inhomogeneous parameters were employed to 
refine non-H atoms. The whole H atoms adopting AFIX 
program were linked with the C atom. Table 1 reveals 
the particular data of complex 1. 
 
Cell Counting Kit-8 detection kit 
The inhibitory effect of the new compound on the 
multiplication of osteosarcoma cells was estimated 
using the Cell Counting Kit-8 assay in accordance 
with the manufacturer’s instructions with some 
modifications. In brief, OUMS-27 osteosarcoma cells 
in the logical growth period were gathered and 
inoculated into 96-well plates with the ultimate fate of 
104 cells / well. The cells were set in an incubator at 
37 ℃ and 5% CO2. After half a day of cultivation, the 
new compound was incubated at a continuous 
concentration (0–80 μM). The cell culture medium 
was abandoned, and a new medium containing  
CCK-8 reagent was poured in the well. After the 
specified treatment, the absorbance of every well was 
estimated at 490 mm. The whole experimental 
procedure was repeated three times, and the data are 
expressed as mean ± SD. 
 
Real-time RT-PCR 
The activity of the LKB1-mTORC1 signalling 
pathway in osteosarcoma cells after using the 
compound was detected by real-time RT-PCR. The 
work was performed following the instructions. 
OUMS-27 osteosarcoma cells in the logical growth 
period were gathered and inoculated into six-well 
plates with an ultimate fate of 106 cells per well. The 
cells were cultured in an incubator at 37 ℃ and 5% 
CO2 for half a day and then fresh compounds were 
injected to the indicated concentration for treatment. 
Table 1 ― Experimental details and crystallographic results of 
compound 1 
Empirical formula C30H28.67Br4MnN4O6.67 
Formula weight 926.50 
Temperature (K) 296.15 
Crystal system monoclinic 
Space group C2/c 
a (Å) 9.3261(12) 
b (Å) 19.246(2) 
c (Å) 18.672(5) 
α (°) 90 
β (°) 101.026(2) 
γ (°) 90 




μ (mm-1) 5.311 
Reflections collected 10145 
Independent reflections 3884 [Rint = 0.0374, Rsigma = 
0.0510] 
Data/restraints/parameters 3884/43/238 
Goodness-of-fit on F2 1.072 
Final R indexes [I>=2σ (I)] R1 = 0.0424, ωR2 = 0.1045 
Final R indexes [all data] R1 = 0.0733, ωR2 = 0.1155 
Largest diff. peak/hole (e Å-3) 0.78/-0.97 
CCDC 2104612 
 




RNA was extracted using TRIZOL reagent. After 
estimating the RNA concentration, it was reverse 
transcribed into cDNA. The relative expression of 
mTORC1 and LKB1 was detected by real-time RT-
PCR, and gapdh was treated as the internal control. 
 
Results and Discussion 
 
Structural characterization 
The results of single crystal analysis and structural 
decomposition gathered at normal temperature explain 
that complex 1 forms the crystal in monoclinic space 
group C2/c, and the asymmetric part concludes half a 
Mn(L)(TBA) entity, a coordinated water molecule, and 
half a non-coordinated water molecule, as shown in  
Fig. 1a. The Mn(II) centrum explains the 6-coordination 
with N1A and N1 atoms (symmetry code is A = −x, y, 
−z + 1/2) from double various nitrogen-containing 
ligands, O1A and O1 atoms from double various fully 
deprotonated TBTA2− ligands, and double coordinated 
water molecules (O1WA, O1W). These components 
produce a crooked octahedral structure. The bond angle 
around the Mn(II) centrum ranges from 86.62(2)° to 
178.57(1)°, and the Mn–O/N bond distances are in the 
range of 2.063(2)–2.133(3) Å. The Mn–O/N bond 
distances are comparable with those observed in other 
Mn(II)-based coordination polymers constructed from 
the carboxylic acid and N-donor co-ligands such as 
{[Mn(dpb)(4,4′-bibp)]ꞏH2O}n (Mn–O/N: 2.087(8)-
2.218(5) Å) and [Mn0.5(PHDI)0.5(DHTA)0.5]n (Mn–O/N: 
2.016-2.136 Å) [22, 23]. In compound 1, the L ligand 
takes the trans conformation. The torsion angle of 
Ndonor⋯N–Csp3⋯Csp3 is 56.06(4)°, and the dihedral angle 
between the planes of the adjacent benzimidazole rings 
in the L ligand is 49.33(1)°. L shows as a µ2-ligand, 
linking with neighbouring metal centers to construct a 
rectilinear 1D [Mn(L)]n chain (Fig. 1b). The TBTA
2− 
ligands show as (κ1-κ0)-(κ1-κ0)-µ2to prolong the 1D 
[Mn(L)]n chain into a 2D lamina by linking with the 
Mn(II) centers (Fig. 1c). The 2D layer can be used as a 
4-connection sql network via the point symbol (44ꞏ62) 
(Fig. 1d). 
PXRD detections were conducted for these 
compounds to estimate the phase purity of the 
compounds (Fig. 2a). The apex of the study and 
simulated PXRD pictures are consistent with one 
 
 
Fig. 1 ― (a) Least building part, (b) one-dimensional Mn-L chain, (c) 2D framework and (d) four-connection sql net of 1 




another, illustrating that the crystal framework is 
authentically a delegate of the blocky crystal 
compounds. The difference in strength may be due to 
the quality of the crystal sample. To understand 
thermal decomposition, TGA studies of compound 1 
were conducted at the temperature range of 25 ℃–
800 ℃ under the condition of N2 atmosphere at a 
heating speed of 10 ℃ min–1 (Fig. 2b). The TGA 
curve of 1 shows that the weight loss is 5.62% in the 
range of 40 ℃–120 ℃, which is consistent with the 
subtraction of water molecules (calcd 5.79%). The 
second weight subtraction (86.72%) is in the range of 
190 ℃–578 ℃. One reason for weight loss is the 
decomposition of TBTA2−and L ligands. The final 
product above the temperature of 600 ℃ might be 
ascribed to MnO (observed: 7.83%, calcd: 7.51%). 
In the IR spectra of 1, there is an absorption peak 
around 3400 cm−1, indicating the existence of water 
molecules. No obvious peak is observed around  
1700 cm−1, illustrating that the H2TBTA ligands are all 
completely deprotonated. The characteristic peak of 
1577 cm−1 for 1 could be attributed to the asymmetric 
(νas(COO)) vibrations. The peak at 1326 cm
−1 is derived 
from symmetric (νs(COO)) vibrations. The separations 
between the characteristic peaks (Δν=[νas(COO)–
νs(COO)]) for demonstrate that the TBTA
2− ligands have 
the monodentate coordination mode (Δν=251 cm−1 for 
1). The broad band of 1 at 1506 cm−1 result from the 
vC=N stretching of the benzimidazole-based ligands. In 
order to research of the luminescence properties of 1,  
the solid-state luminescence spectra of ligand L and 1 
were investigated at room temperature (Fig. S2, 
Supplementary Data). The free L ligand displays the 
emission maxima at 319 nm and the excitation maxima 
at 298 nm, which can be attributed to π*→π transitions. 
Compound 1 emits strong luminescence with maxima 
peaks at 312 nm (λex = 279 nm). In comparison with 
ligand L, the emission maxima of 1 has slight blue-
shifted of 7 nm. The strong luminescence emission of 
compound 1 may due to the ligand-to-ligand charge 
transfer because their similar profiles. 
 
Inhibition of the new compound on the proliferation of 
OUMS-27 osteosarcoma cells 
After the design and formation of the new compound 
with fresh structure, its treatment activation on the 
proliferation of OUMS-27 osteosarcoma cells was 
determined. OUMS-27 osteosarcoma cells in the logical 
growth period accumulated and fostered into the cell 
culture plate, and then the compound was injected at 
continuous different dilutions. The proliferation of 
metastatic bone cancer cells was evaluated via CCK-8 
assay. As shown in Fig. 3, the proliferation of OUMS-27 
osteosarcoma cells in the control model was high. After 
using the fresh compound, the proliferation of OUMS-
 
 




Fig. 3 ― Treatment activation on the proliferation of OUMS-27 
osteosarcoma cells 
 




27 osteosarcoma cells significantly reduced, which is 
tremendously unequal from the control model. The 
inhibition of the new compound was much stronger than 
the positive control medicine 5-Fu. 
 
Regulated LKB1-mTORC1 signalling pathway activation in 
osteosarcoma cells 
The compound showed excellent regulatory 
influence on the LKB1-mTORC1 signalling pathway 
in osteosarcoma cells. OUMS-27 osteosarcoma cells 
in the logical growth period were accumulated and 
fostered into the cell culture medium, and then the 
compound was injected at indicated various 
concentrations. Real-time RT-PCR was recommended 
to evaluate the activation of the LKB1-mTORC1 
signalling pathway in the osteosarcoma cells. The 
new compound showed great inhibitory activation on 
the proliferation of the osteosarcoma cells. As 
previously reported, the LKB1-mTORC1 signalling 
pathway shows a vital part in the development of 
osteosarcoma development. Thus, real-time RT-PCR 
was further implemented, and the activity of the 
LKB1-mTORC1 signalling pathway was evaluated. 
As shown in Fig. 4, the level of LKB1 tremendously 
reduced and the level of mTORC1 decreased in the 
osteosarcoma cells in contrast to the control group. 
Obvious diversity occurred between two groups. 
Under the injection of the fresh compound, the 
relative expression of LKB1 was regulated and the 
mTORC1 level significantly reduced. The biological 
activity of the fresh compound was dose dependent. 
 
Conclusions 
We prepared Mn(II)-based coordination polymer 
by reacting Mn(OAc)2ꞏ2H2O with the flexible  
ligand 1,4-bis(5,6-dimethylbenzimidazol-1-yl)-2-
butylene in the aid of the carboxylic acid ligand 
tetrabromoterephthalic acid. The prepared coordination 
polymer 1 was structurally discussed via single-crystal 
XRD and was further detected by IR spectral, EA, 
PXRD, and TG analyses. The cell counting Kit-8 
detection kit revealed that the compound could 
tremendously lower the proliferation of the osteosarcoma 
cells. Moreover, the activity of the LKB1-mTORC1 
signalling pathway in the osteosarcoma cells was 
inhibited by the new compound in a dose-dependent 
manner. The compound could be an extraordinary 
candidate for osteosarcoma therapy by inhibiting the 
proliferation of osteosarcoma cells and activity  
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